{
    "clinical_study": {
        "@rank": "94047", 
        "arm_group": {
            "arm_group_label": "Melatonin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate dose escalation of melatonin in pediatric oncology patients with\n      relapsed solid tumors.  The purpose of this study is to determine the safety of melatonin at\n      a dose up to 20 mg daily, as well as to determine the maximum tolerated dose of melatonin."
        }, 
        "brief_title": "Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed Malignant Solid Tumor", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be able to take medication by mouth either by swallowing, chewing or\n             sublingual routes.\n\n          -  Patients must have a documented life expectancy of \u2265 8 weeks.\n\n          -  Patients must have histologic or radiographic evidence of a relapsed malignant solid\n             tumor.  Intrinsic brain stem tumors or optic pathway gliomas may be diagnosed by\n             clinical and radiologic methods.\n\n          -  Patient, parent, legal representative and/or guardian must  sign a written informed\n             consent. Assent, when appropriate, will be  obtained according to institutional\n             guidelines.\n\n          -  Minimum Weight Requirements: Dose level 1 - 22.2kg, Dose level 2 - 11.1kg, Dose level\n             3 - 5.6kg\n\n          -  Patients must be taking a stable dose (with no additions, modifications or deletions)\n             of chemotherapy started \u2265 14 days prior study enrollment.\n\n          -  Prescribed Chemotherapy drug(s) must not be known to interact with melatonin\n\n          -  Adequate Bone Marrow Function Defined as:\n\n               1. Patients with solid tumors without bone marrow involvement:\n\n                    -  Peripheral absolute neutrophil count (ANC) \u2265 1 x109/L\n\n                    -  Platelet count \u2265 50 X 109/L  (transfusion independent, defined as not\n                       receiving platelet transfusions within a 7 day period prior to enrollment)\n\n                    -  Hemoglobin \u2265 80 g/L (may receive RBC transfusions)\n\n               2. Patients with known bone marrow metastatic disease are eligible for study but\n                  not evaluable for hematologic toxicity.\n\n                    -  Must not be known to be refractory to red cell or platelet transfusions.\n\n                    -  These patients do not need to meet the bone marrow function requirements,\n                       as hematological toxicity will not be measured due to metastatic disease.\n\n          -  Adequate Liver Function Defined as:\n\n               -  Total Bilirubin \u2264 1.5 x upper limit of normal (ULN) for age.\n\n               -  ALT \u2264 1.5 x ULN for age.\n\n        Exclusion Criteria:\n\n          -  Chemotherapy: Melatonin inhibits the action of doxorubicin\n\n          -  Growth factors that support white cell number administered \u2264 7 days prior to\n             enrollment.\n\n          -  Patients requiring corticosteroids who are not on a stable or decreasing dose of\n             corticosteroid for \u2265 14 days.\n\n          -  Patients prescribed immunosuppressant therapy that is not specifically utilized for\n             chemotherapy purposes.  Patient prescribed: Cyclosporine, Mycophenolate  Mofetil HCL,\n             Tacrolimus, Sirolimus and Azathioprine should be excluded\n\n          -  Patients prescribed anti-coagulation therapy (Warfarin, Low Molecular Weight Heparin\n             (LMWH), or System Heparin Therapy)\n\n          -  Concomitant medications that are known CYP1A2 inhibitors interact with Melatonin.\n\n          -  Patients prescribed megace, corticosteroids and periactin started \u2264 14 days prior to\n             study enrollment.\n\n          -  Patients taking the following medications:  benzodiazepines, nifedipine, NSAID's, ASA\n             and/or Beta Blockers\n\n          -  Patients \u2264 7 days post-operative from any surgical procedure.\n\n          -  Patients with any signs of active post-operative bleeding.\n\n          -  Patients with an infection that is not responding to anti-microbial therapy.\n\n          -  Any condition that would negatively impact effective gut absorption and/or swallowing\n             of study medication.\n\n          -  Patients in the opinion of the investigator may not be able to comply with study\n             protocol requirements\n\n          -  Patients already receiving melatonin are excluded from the study.\n\n          -  Allergies to the medicinal and/or non-medicinal ingredients of melatonin which\n             include: Melatonin, Calcium Salicate, Croscarmellose Sodium, IsoMalt, Magnesium\n             Stearate, Microcrystalline Cellulose.\n\n          -  As melatonin can cause fatigue, patients taking melatonin should refrain from driving\n             or operating machinery within 5 hours of taking the melatonin."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858155", 
            "org_study_id": "C17 MEL P1"
        }, 
        "intervention": {
            "arm_group_label": "Melatonin", 
            "intervention_name": "Melatonin", 
            "intervention_type": "Drug", 
            "other_name": "SISU Melatonin"
        }, 
        "intervention_browse": {
            "mesh_term": "Melatonin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 6, 2013", 
        "location": [
            {
                "contact": {
                    "email": "djohnston@cheo.on.ca", 
                    "last_name": "Donna Johnston, MD", 
                    "phone": "613-737-7600", 
                    "phone_ext": "2751"
                }, 
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L1"
                    }, 
                    "name": "Children's Hospital of Eastern Ontario"
                }, 
                "investigator": {
                    "last_name": "Donna Johnston, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rrassekh@cw.bc.ca", 
                    "last_name": "Rod Rassekh, MD", 
                    "phone": "604-875-2644"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "V6H 3V4"
                    }, 
                    "name": "Children's & Women's Health Centre of British Columbia"
                }, 
                "investigator": {
                    "last_name": "Rod Rassekh, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors", 
        "overall_official": {
            "affiliation": "Children's Hospital of Eastern Ontario", 
            "last_name": "Donna Johnston, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada - Natural Health Products Directorate", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated daily dose of melatonin.", 
            "safety_issue": "Yes", 
            "time_frame": "8 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858155"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of dose limiting toxicities during 8 weeks of melatonin therapy.", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks"
            }, 
            {
                "measure": "Peak plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) of Melatonin.", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks"
            }, 
            {
                "measure": "The quantity of cytokines will be measured during 8 weeks of melatonin therapy.", 
                "safety_issue": "Yes", 
                "time_frame": "8 Weeks"
            }, 
            {
                "measure": "Change from Baseline in weight after 8 weeks of therapy.", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }
        ], 
        "source": "C17 Council", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "C17 Council", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}